ABBV - AbbVie Inc
A biopharmaceutical leader best known for Humira — the world's best-selling drug — now pivoting its pipeline toward immunology, oncology, and neuroscience.
Finlify Score
33.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$257.12
+0.83%
52W Range
$190.75 - $267.47
Market Cap
$453.1B
+0.8%Compared to previous day
2026 Q1 Revenue
$15.0B
-9.7%Changes from last reporting quarter
2026 Q1 EPS
$0.39
Diluted shares
Analyst Rating
39 analysts in latest ratings feed
RSI
40.1
40-70 moderate
2Y Range Position
90%
-3.9% from high / +57.0% from low
Beta
0.21
Relative to market benchmark
MACD
-1.02
MACD line 0.59 / signal line 1.61
Fundamental Trend
Growth 9.2Financial Health
Quality 47.6Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID33.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $15.0B-9.7% | $16.6B+5.3% | $15.8B+2.3% | $15.4B+15.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $4.0B-12.2% | $4.5B+138.7% | $1.9B-61.1% | $4.9B+31.1% |
| Net Income | $695M-61.7% | $1.8B+876.3% | $186M-80.2% | $938M-27.1% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
The Finlify signal for ABBV is AVOID, with an overall score of 42.6/100, which appears to indicate a generally unfavorable quantitative outlook for the asset based on the provided data.
Technical
Technically, the asset shows moderate Relative Strength at 54.8/100 and somewhat stronger Accumulation / Volume at 67.2/100, suggesting some buying interest. ABBV has experienced a significant 60-day return of 23.7% and is only -2.2% from its 52-week high, while its RSI(14) of 58.9 indicates it is not currently in overbought territory.
Fundamentals
The Fundamental Trend score is notably low at 9.2/100, which may suggest underlying fundamental weaknesses or deteriorating conditions. Valuation metrics appear elevated, with a P/E ratio of 105.7x, P/B of 94.4x, and P/S of 7.3x, potentially indicating the asset is trading at a premium. Despite a Financial Quality score of 47.6/100, the asset does offer a dividend yield of 2.69% and exhibits a low beta of 0.3, suggesting lower volatility compared to the broader market.
Macro Context
The current macro environment, with CPI YoY at 3.7% and Core PCE YoY at 3.3%, suggests persistent inflationary pressures. With the 10-year Treasury yield at 4.7% and the 2-year at 4.2%, the positive yield spread of 0.5% may indicate a less immediate recessionary concern, but higher rates could still influence valuation multiples for growth-oriented assets.
Key Risks
- The very low Fundamental Trend score of 9.2/100 may indicate significant underlying fundamental challenges.
- Elevated valuation multiples (P/E 105.7x, P/B 94.4x, P/S 7.3x) could suggest the asset is overvalued relative to its fundamentals.
- The upcoming earnings announcement on 2026-07-31 could introduce significant price volatility.